Printer Friendly

RIBI IMMUNOCHEM AND LIDAK PHARMACEUTICALS TO COLLABORATE ON POTENTIAL SECOND-GENERATION THERACCINE TECHNOLOGY

 HAMILTON, Mont., Aug. 24 /PRNewswire/ -- Ribi ImmunoChem (NASDAQ: RIBI) and Lidak Pharmaceuticals (NASDAQ: LDAKA) have entered into an agreement under which Ribi has granted Lidak an experimental license to use Ribi's melanoma cell lines in the clinical development of Lidak's Large Multivalent Immunogen (LMI) technology. In return, Lidak has granted Ribi an option for an exclusive license to use the LMI technology with Ribi's melanoma cell lines for the treatment of melanoma, should preclinical and human clinical development of the technology prove successful. This agreement does not restrict Lidak from developing or licensing its LMI technology for other applications.
 Ribi has an exclusive license to the melanoma cell lines from the University of Southern California; the cell lines are used in the manufacture of Ribi's MELACINE(R) melanoma theraccine (therapeutic vaccine), which is currently in two pivotal Phase III human clinical studies for the treatment of melanoma. If successful, the Lidak LMI technology used with the Ribi-USC melanoma cell lines may lead to the next generation of cancer theraccines.
 LMI may have application in improving human immune responses to various cancer and viral antigens. LMI technology incorporate santigenic material on cell-sized microspheres, creating a "virtual" cancer cell or virus that is non-virulent and is relatively large and well-recognized by the immune system compared to individual pieces of antigenic material. Results of preclinical testing of LMI in a mouse tumor model indicate that LMI stimulated a protective immune response, including a satisfactory cellular response. A cellular (or cell- mediated) immune response has been found to be more effective against cancer and viral diseases than a humoral or antibody-based response.
 "We are very pleased to collaborate in this effort to advance the progress of immunotherapy for cancer and other serious human infectious diseases," said Robert E. Ivy, chief executive officer, president and chairman of Ribi ImmunoChem. "The goal of improving the human immune response, and thus human healthcare, underlies this agreement as well as our license arrangements with SmithKline Beecham for infectious disease vaccines and Biomira Inc. for cancer theraccines."
 Ribi ImmunoChem Research Inc., a biopharmaceutical company founded in 1981, is a leader in the development of immunostimulants for use in preventing and treating human disease.
 -0- 8/24/93
 /CONTACT: Jeffrey S. McDowell, of Ribi ImmunoChem Research Inc., 406-363-6214, ext. 153; or Michele Fasano, of Lippert/Heilshorn & Associates Inc., 212-838-3777, for Ribi ImmunoChem/
 (RIBI LDAKA)


CO: Ribi ImmunoChem Research Inc.; Lidak Pharmaceuticals ST: Montana IN: MTC SU: CON

JH -- SE001 -- 5301 08/24/93 07:55 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1993
Words:416
Previous Article:CONSUMER FINANCES CONTINUE TO HEAL;
Next Article:CASCADE ANNOUNCES EXECUTIVE MANAGEMENT CHANGES
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters